Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Written by Emily J. Thompson, Senior Investment Analyst
Source: WSJ
Impact of Drug Price Cuts: Global pharmaceutical stocks experienced a decline after President Trump announced plans to reduce drug prices for Americans by up to 80%.
Affected Companies: Novo Nordisk saw a 5% drop in shares, while other companies like AstraZeneca, Novartis, and GSK also faced significant losses due to their reliance on U.S. sales.
Analyst Views on ROG
Wall Street analysts forecast ROG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROG is 281.18 USD with a low forecast of 105.00 USD and a high forecast of 457.36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 98.250
Low
105.00
Averages
281.18
High
457.36
Current: 98.250
Low
105.00
Averages
281.18
High
457.36
About ROG
Rogers Corporation designs, develops, manufactures and sells engineered materials and components. Its segments include Advanced Electronics Solutions (AES) and Elastomeric Material Solutions (EMS) and Other. The AES segment designs, develops, manufactures and sells circuit materials, ceramic substrate materials, busbars and cooling solutions for applications in the EV/HEV, automotive, aerospace and defense, renewable energy, wireless infrastructure, mass transit, industrial, connected devices and wired infrastructure markets. The EMS segment designs, develops, manufactures and sells engineered material solutions for a variety of applications and markets. These include polyurethane and silicone materials used in cushioning, gasketing and sealing, and vibration management applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, and other markets. The Other segment consists of elastomer components for applications in the general industrial market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
